Skip to content


Hemlibra (emicizumab) is an antibody pharmaceutical. Emicizumab was first approved as Hemlibra on 2017-11-16. It is used to treat hemophilia a in the USA. It has been approved in Europe to treat hemophilia a. It is known to target coagulation factor IX and coagulation factor X.
Trade Name Hemlibra
Common Name Emicizumab
Indication hemophilia a
Drug Class Monoclonal antibodies: humanized, cardiovascular indications
Get full access now